ULTRAGENYX PHARMACEUTICAL INC. - COMMON STOCK

NetDania - New 12 months High: ULTRAGENYX PHARMACEUTICAL INC. - COMMON STOCK

13 9 2024 10:04:25 提供 NetDania Notify

Ultragenyx to Participate in Investor Conferences in September

29 8 2024 16:30:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months High: ULTRAGENYX PHARMACEUTICAL INC. - COMMON STOCK

29 8 2024 10:17:24 提供 NetDania Notify

NetDania - New 12 months High: ULTRAGENYX PHARMACEUTICAL INC. - COMMON STOCK

28 8 2024 10:40:17 提供 NetDania Notify

NetDania - New 12 months High: ULTRAGENYX PHARMACEUTICAL INC. - COMMON STOCK

26 8 2024 12:35:19 提供 NetDania Notify

NetDania - New 12 months High: ULTRAGENYX PHARMACEUTICAL INC. - COMMON STOCK

22 8 2024 09:45:08 提供 NetDania Notify

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

21 8 2024 16:30:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months High: ULTRAGENYX PHARMACEUTICAL INC. - COMMON STOCK

21 8 2024 10:00:12 提供 NetDania Notify

Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update

01 8 2024 16:05:39 提供 Nasdaq GlobeNewswire

Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update

25 7 2024 16:05:00 提供 Nasdaq GlobeNewswire

Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium

24 7 2024 08:00:00 提供 Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

19 7 2024 16:05:00 提供 Nasdaq GlobeNewswire

Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program

17 7 2024 16:05:00 提供 Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

20 6 2024 16:30:00 提供 Nasdaq GlobeNewswire

Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

13 6 2024 20:49:09 提供 Nasdaq GlobeNewswire

Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

12 6 2024 16:05:00 提供 Nasdaq GlobeNewswire

Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)

12 6 2024 16:00:00 提供 Nasdaq GlobeNewswire

Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)

11 6 2024 17:47:59 提供 Nasdaq GlobeNewswire

Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference

04 6 2024 16:05:00 提供 Nasdaq GlobeNewswire

Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

30 5 2024 16:00:00 提供 Nasdaq GlobeNewswire